AstraZeneca Pharma surges on planning to launch Breztri Aerosphere in January 2025
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Astrazeneca Pharma India is currently trading at Rs. 6518.15, up by 120.50 points or 1.88% from its previous closing of Rs. 6397.65 on the BSE.
The scrip opened at Rs. 6450.05 and has touched a high and low of Rs. 6588.35 and Rs. 6450.05 respectively. So far 543 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 8139.85 on 30-Sep-2024 and a 52 week low of Rs. 4050.15 on 21-Mar-2024.
Last one week high and low of the scrip stood at Rs. 7392.55 and Rs. 6362.75 respectively. The current market cap of the company is Rs. 15994.13 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 8.00% and 17.01% respectively.
AstraZeneca Pharma India is all set to launch Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere) in January 2025 in India. Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).
